ArticleGene therapy2003
High-efficiency plasmid gene transfer into dystrophic muscle.
Article in Gene therapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 81 citations in OpenAlex.
- In Vivo Electroporation of Plasmid DNA into the Skeletal Muscle of Dystrophic Mouse Models.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Wearable Bioelectronics for Home-Based Monitoring and Treatment of Muscle Atrophy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Enhancing In Vivo Electroporation Efficiency through Hyaluronidase: Insights into Plasmid Distribution and Optimization Strategies.Pharmaceutics · 2024Article
- CORP: Gene delivery into murine skeletal muscle using in vivo electroporation.Journal of applied physiology (Bethesda, Md. : 1985) · 2022Review
- Targeting Muscle-Resident Single Cells ThroughFrontiers in physiology · 2022Article
- A Critical Review of Electroporation as A Plasmid Delivery System in Mouse Skeletal Muscle.International journal of molecular sciences · 2019Review
- miR-424-5p reduces ribosomal RNA and protein synthesis in muscle wasting.Journal of cachexia, sarcopenia and muscle · 2018Article
- Growth differentiation factor-15 is associated with muscle mass in chronic obstructive pulmonary disease and promotes muscle wasting in vivo.Journal of cachexia, sarcopenia and muscle · 2016Article
- Gene Electrotransfer: A Mechanistic Perspective.Current gene therapy · 2016Review
- FHL1 activates myostatin signalling in skeletal muscle and promotes atrophy.FEBS open bio · 2015Article
- Gene and cell-mediated therapies for muscular dystrophy.Muscle & nerve · 2013Review
- Skeletal muscle regeneration in mice is stimulated by local overexpression of V1a-vasopressin receptor.Molecular endocrinology (Baltimore, Md.) · 2011Article
- Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Quantitative real-time PCR study on persistence of pDNA vaccine pVax-Hsp60 TM814 in beef muscles.Genetic vaccines and therapy · 2008Article
- Enhanced effect of microdystrophin gene transfection by HSV-VP22 mediated intercellular protein transport.BMC neuroscience · 2007Article
- Enhancement of plasmid-mediated gene therapy for muscular dystrophy by directed plasmid integration.Proceedings of the National Academy of Sciences of the United States of America · 2006Article
- Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy.Journal of muscle research and cell motility · 2006Review
- IGF-I increases bone marrow contribution to adult skeletal muscle and enhances the fusion of myelomonocytic precursors.The Journal of cell biology · 2005Article
- Angiogenic and antiangiogenic gene therapy.Gene therapy · 2005Review
- Nonviral gene transfer to skeletal, smooth, and cardiac muscle in living animals.American journal of physiology. Cell physiology · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficiency of plasmid gene transfer in skeletal muscle is significantly enhanced by pretreatment with hyaluronidase and the application of an electrical field to the muscle following the injection of plasmid DNA, a process referred to as electrotransfer. However, the presence of increased levels of connective tissue in muscular dystrophies, such as Duchenne muscular dystrophy (DMD), may affect the efficiency of this process. Here we demonstrate that the efficiency of electrotransfer is not affected by increased levels of connective tissue in the mdx mouse model of DMD and that any damage induced by the electrotransfer process is not exacerbated in the dystrophic phenotype. However, increasing the concentration of hyaluronidase does not improve transfection efficiencies further. Unlike direct injection of plasmid DNA, the efficiency of electrotransfer is not dependent upon the sex and age of mice used. The combined treatment of hyaluronidase and electrotransfer results in highly efficient gene transfer in dystrophic muscle with limited muscle damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.